Articles - 6ban mentioned but not cited (1)
- Crystal structure of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (hROR1). Guarino SR, Di Bello A, Palamini M, Capillo MC, Forneris F. Acta Crystallogr F Struct Biol Commun 78 185-192 (2022)
Reviews citing this publication (10)
- Biology drives the discovery of bispecific antibodies as innovative therapeutics. Nie S, Wang Z, Moscoso-Castro M, D'Souza P, Lei C, Xu J, Gu J. Antib Ther 3 18-62 (2020)
- ROR1: an orphan becomes apparent. Kipps TJ. Blood 140 1583-1591 (2022)
- Bispecific antibodies in cancer immunotherapy. Rader C. Curr Opin Biotechnol 65 9-16 (2020)
- Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Strohl WR, Naso M. Antibodies (Basel) 8 (2019)
- Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. Hofland T, Eldering E, Kater AP, Tonino SH. Int J Mol Sci 20 (2019)
- Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. Karvonen H, Barker H, Kaleva L, Niininen W, Ungureanu D. Cells 8 (2019)
- Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Cancers (Basel) 13 (2021)
- The Role of Bispecific Antibodies in Non-Hodgkin's Lymphoma: From Structure to Prospective Clinical Use. Tavarozzi R, Manzato E. Antibodies (Basel) 11 16 (2022)
- The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Menck K, Heinrichs S, Baden C, Bleckmann A. Cells 10 (2021)
- Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. Kamrani A, Mehdizadeh A, Ahmadi M, Aghebati-Maleki L, Yousefi M. Expert Opin Ther Targets 23 447-456 (2019)
Articles citing this publication (25)
- Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform. Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, Einsele H, Rader C, Hudecek M. Mol Ther 27 287-299 (2019)
- One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics. Chen W, Yang F, Wang C, Narula J, Pascua E, Ni I, Ding S, Deng X, Chu ML, Pham A, Jiang X, Lindquist KC, Doonan PJ, Van Blarcom T, Yeung YA, Chaparro-Riggers J. MAbs 13 1871171 (2021)
- A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era. Robinson HR, Qi J, Cook EM, Nichols C, Dadashian EL, Underbayev C, Herman SEM, Saba NS, Keyvanfar K, Sun C, Ahn IE, Baskar S, Rader C, Wiestner A. Blood 132 521-532 (2018)
- A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells. Aschmoneit N, Steinlein S, Kühl L, Seifert O, Kontermann RE. Sci Rep 11 13880 (2021)
- BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Mhibik M, Gaglione EM, Eik D, Kendall EK, Blackburn A, Keyvanfar K, Baptista MJ, Ahn IE, Sun C, Qi J, Rader C, Wiestner A. Blood 138 1843-1854 (2021)
- ROR1-targeting switchable CAR-T cells for cancer therapy. Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, Rader C. Oncogene 41 4104-4114 (2022)
- Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues. Hwang D, Nilchan N, Nanna AR, Li X, Cameron MD, Roush WR, Park H, Rader C. Cell Chem Biol 26 1229-1239.e9 (2019)
- Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. Hatterer E, Chauchet X, Richard F, Barba L, Moine V, Chatel L, Broyer L, Pontini G, Bautzova T, Juan F, Calloud S, Bosson N, Charreton M, Masternak K, Buatois V, Shang L. MAbs 12 1739408 (2020)
- The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Hu EY, Do P, Goswami S, Nunes J, Chiang CL, Elgamal S, Ventura AM, Cheney C, Zapolnik K, Williams E, Mani R, Frissora F, Mo X, Waldmeier L, Beerli RR, Peng H, Rader C, Long M, Grawunder U, Byrd JC, Muthusamy N. Blood Adv 5 3152-3162 (2021)
- Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications. Goydel RS, Weber J, Peng H, Qi J, Soden J, Freeth J, Park H, Rader C. J Biol Chem 295 5995-6006 (2020)
- Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Chen X, Amar N, Zhu Y, Wang C, Xia C, Yang X, Wu D, Feng M. J Immunother Cancer 8 (2020)
- Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Tomar S, Zhang J, Khanal M, Hong J, Venugopalan A, Jiang Q, Jiang Q, Sengupta M, Miettinen M, Li N, Pastan I, Ho M, Hassan R. Mol Cancer Ther 21 1195-1206 (2022)
- Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C. J Immunother Cancer 10 e004850 (2022)
- Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA. Commun Biol 4 310 (2021)
- A high throughput bispecific antibody discovery pipeline. Segaliny AI, Jayaraman J, Chen X, Chong J, Luxon R, Fung A, Fu Q, Jiang X, Rivera R, Ma X, Ren C, Zimak J, Hedde PN, Shang Y, Wu G, Zhao W. Commun Biol 6 380 (2023)
- Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice. Chen X, Chen Y, Liang R, Xiang L, Li J, Zhu Y, He H, Huang L, Zuo D, Li W, Liang X, Dong S, Hu S, Ho M, Feng M. Mol Cancer Ther 21 149-158 (2022)
- Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. Qi J, Hymel D, Nelson CG, Burke TR, Rader C. Front Immunol 10 1994 (2019)
- Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release. Aschmoneit N, Kühl L, Seifert O, Kontermann RE. J Immunother Cancer 9 e003616 (2021)
- Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. Dave Z, Vondálová Blanářová O, Čada Š, Janovská P, Zezula N, Běhal M, Hanáková K, Ganji SR, Krejci P, Gömöryová K, Peschelová H, Šmída M, Zdráhal Z, Pavlová Š, Kotašková J, Pospíšilová Š, Bryja V. Front Cell Dev Biol 10 838871 (2022)
- Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies. Loh HP, Mahfut FB, Chen SW, Huang Y, Huo J, Zhang W, Lam KP, Xu S, Yang Y. MAbs 15 2231129 (2023)
- ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes. Shi F, Mendrola JM, Sheetz JB, Wu N, Sommer A, Speer KF, Noordermeer JN, Kan ZY, Perry K, Englander SW, Stayrook SE, Fradkin LG, Lemmon MA. Cell Rep 37 109834 (2021)
- Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells. Huang S, Segués A, Waterfall M, Wright D, Vayssiere C, van Duijnhoven SMJ, van Elsas A, Sijts AJAM, Zaiss DM. Biomolecules 12 1331 (2022)
- Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1. Fierle JK, Brioschi M, de Tiani M, Wetterwald L, Atsaves V, Abram-Saliba J, Petrova TV, Coukos G, Dunn SM. Cell Rep Med 2 100362 (2021)
- T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. Riccio G, Ricardo AR, Passariello M, Saraiva K, Rubino V, Cunnah P, Mertens N, De Lorenzo C. J. Immunother. 42 1-10 (2019)
- eIg-based bispecific T-cell engagers targeting EGFR: Format matters. Kühl L, Schäfer AK, Kraft S, Aschmoneit N, Kontermann RE, Seifert O. MAbs 15 2183540 (2023)
Related citations provided by authors (1)
- Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.. Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C PLoS One 6 e21018 (2011)